NDAINTRAVENOUSPOWDER
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3
Mechanism of Action
Prostacyclin Receptor Agonists
Pharmacologic Class:
Prostacyclin Receptor Agonist
Clinical Trials (3)
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Started Oct 2020
20 enrolled
Pulmonary HypertensionSchistosomiasis
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Started Oct 2020
372 enrolled
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Started May 2017
0Pulmonary Arterial Hypertension
Loss of Exclusivity
LOE Date
Feb 1, 2031
59 months away
Patent Expiry
Feb 1, 2031
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7205302 | Oct 31, 2026 | SubstanceProduct | U-1797 |
| 7205302*PED | Apr 30, 2027 | — | |
| 9173881 | Aug 12, 2029 | U-1798 | |
| 9173881*PED | Feb 12, 2030 | — | |
| 9284280 | Jun 25, 2030 | U-1831 |